Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- dostarlimab
- Truseltiq (infigratinib)
Interactions between your drugs
dostarlimab infigratinib
Applies to: dostarlimab, Truseltiq (infigratinib)
Using infigratinib may decrease the effects of dostarlimab, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact or may choose to postpone treatment with dostarlimab. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
infigratinib food
Applies to: Truseltiq (infigratinib)
Infigratinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with infigratinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Fam-trastuzumab deruxtecan
Trastuzumab deruxtecan (Enhertu, T-DXd) is a treatment for breast cancer, advanced stomach cancer ...
Selpercatinib
Selpercatinib is used for non small cell lung cancer, solid tumors, thyroid cancer
Dabrafenib
Dabrafenib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Trametinib
Trametinib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.